Allergan Aesthetics, an AbbVie company, has unveiled four major posters at the American Academy of Dermatology (AAD) Meeting, spotlighting the safety and efficacy of its latest products and shedding light on the evolving aesthetic concerns of a new patient population.

 

"At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio," said John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics. 

 

"Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns."

 

Among the highlights was TrenibotulinumtoxinE (TrenibotE), an investigational first-in-class botulinum neurotoxin serotype E. 

 

Data from an 18-week, open-label Phase 3 study tracking up to three repeat treatments for glabellar lines showed TrenibotE was well-tolerated, maintained a consistent safety profile, and triggered no neutralizing antibody development. Patients experienced rapid results—as soon as eight hours after administration—with effects lasting 2–3 weeks.

 

“TrenibotE rapidly reduced glabellar line severity, with consistent efficacy over 3 sequential open-label treatments based on investigator and participant assessments,” the study reported.

 

Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments. An electronic survey of U.S. health care professionals revealed that 52% of these patients express concerns about their facial appearance during treatment.

 

Key survey findings include: 32% of GLP-1-treated patients are new to aesthetic practices.

Top barriers to treatment: cost (82%) and fear of unnatural results (58%).

Patient demographics: predominantly white (64%), female (70%), and aged 30–49 (56%).

 

The data underscores Allergan’s dual focus on advancing innovative treatments like TrenibotE while understanding the shifting mindset of emerging aesthetic patients.